Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act 1934
Date of
Report (date of earliest event reported): April 16, 2009
JIANGBO
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
Florida
(State or
other jurisdiction of incorporation)
|
333-86347
|
65-1130026
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
Middle
Section, Longmao Street, Area A, Laiyang Waixiangxing Industrial
Park
|
|
Laiyang
City, Yantai, Shandong Province, People’s Republic of China
265200
|
(Address
of principal executive offices and zip code)
(0086)
535-7282997
(Registrant's
telephone number including area code)
(Registrant's
former name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of registrant under any of the following
provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR
240.14a-12(b))
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
The
statements contained in this Form 8-K that are not purely historical are
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These include statements about the Registrant’s expectations,
beliefs, intentions or strategies for the future, which are indicated by words
or phrases such as “anticipate,” “expect,” “intend,” “plan,” “will,” “the
Registrant believes,” “management believes” and similar words or phrases. The
forward-looking statements are based on the Registrant’s current expectations
and are subject to certain risks, uncertainties and assumptions. The
Registrant’s actual results could differ materially from results anticipated in
these forward-looking statements. All forward-looking statements included in
this document are based on information available to the Registrant on the date
hereof, and the Registrant assumes no obligation to update any such
forward-looking statements.
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal
Year.
On April
16, 2009, the Registrant received confirmation from the Department of State of
the State of Florida that the Certificate of Amendment to its Amended and
Restated Articles of Incorporation (“Certificate of Amendment”) to effect a
change of its name from Genesis Pharmaceuticals Enterprises, Inc. to “Jiangbo
Pharmaceuticals, Inc.” was duly filed (the “Name Change”). The Board of
Directors of the Registrant as well as the holders of a majority of the
outstanding shares of the Registrant’s voting stock approved the Name Change by
written consent. The Registrant has taken the necessary steps to change its
symbol and CUSIP Number.
A form of
the Certificate of Amendment that was filed with the Department of State of the
State of Florida is attached to this Form 8-K as Exhibit 3.1.
Item
9.01 Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
|
3.1
|
Certificate
of Amendment to the Registrant’s Articles of
Incorporation
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
JIANGBO
PHARMACEUTICALS, INC.
|
|
|
|
|
|
By: /s/ Wubo
Cao
|
|
|
Name:
Wubo Cao
|
|
|
Title:
Chief Executive Officer
|
Dated:
April 21, 2009